The limited duration of humoral responses to vaccination is a key issue in the fight against infectious diseases, as antibody levels wane over time, leaving individuals vulnerable to reinfection.
Stanford scientists have discovered that bispecific antibodies can selectively bind cancer cells and block the CD47-SIRPα "don't eat me signal" to efficiently clear tumors with negligible toxicity.
Researchers at Stanford, funded in part by the Chan Zuckerberg Biohub, have developed PMD (Protect, Modify, Deprotect), an immunofocusing strategy that can be used in vaccine development for the generation of antibodies targeting a specific epitope.
Stanford researchers have developed a PCR-based method that detects disease-relevant, isotype-specific antibodies and can be used to diagnose allergy. Allergy is a prevalent immune hypersensitivity disease that affects more than 20% of the US population.
Researchers in Prof. Irving Weissman's lab have developed and patented antibodies and methods to prevent the formation of teratomas from human pluripotent stem cells used for regenerative medicine, cell therapy or research.
RNKp30 monoclonal antibodies were generated by immunizing BALB/c mice with rNKp30-Fc fusion protein. The rNKp30-Fc fusion protein is a soluble protein consisting of the extracellular domain of rNKp30 fused to the Fc domain of human IgG1.
Cancers including breast, lung, colon and prostate account for almost ten million deaths worldwide every year. The main cause of cancer deaths is metastasis, which is the propensity of cancer cells to spread throughout the body.
Lab Designation: RB6 8C5; A rat-mouse hybridoma cell line producing a monoclonal IgG2b rat AB which recognizes most, if not all, granuloytes and granolucyte precursors in the mouse bone marrow.
The invention consists of the ability to treat inflammatory and autoimmune disorders, particularly but not exclusively those involving mucosal sites such as in the chronic inflammatory bowel disease, by blocking or altering 4B7 interactions with vascular and extracellular matr
Researchers in Prof. Mark Kay's laboratory have continued to develop novel recombinant adeno-associated viral (AAV) capsids via capsid gene shuffling that transduce human hepatocytes at high efficiency in vivo.
Researchers at Stanford have discovered a therapeutic strategy to overcome off-target red blood cell (RBC) toxicity associated with anti-CD47 antibody cancer therapies and possibly antibody-mediated autoimmune anemia and thrombocytopenia.